Literature DB >> 24964694

Defining the scope of health technology assessment and types of health economic evaluation.

Pimwara Tanvejsilp, Surachat Ngorsuraches.   

Abstract

Health Technology Assessment (HTA) is a process that uses principles from across various disciplines, including medicine, sociology, economics, and ethics, to evaluate health technologies. Policy makers can use HTA as a tool to assess health technologies in a systematic, unbiased, transparent, and robust manner in order to make informed and evidence-based decisions. Generally, researchers begin an HTA by defining the overall scope of the assessment, after which they choose an appropriate type of health economic evaluation, one of the most important elements of HTA. The objective of this article is to provide recommendations about the scope of HTA as well as guidance on the kinds of health economic evaluation that are appropriate in the context of the new Thai HTA guidelines. A well-defined research question that addresses five major components-target population, technology or intervention, comparator outcome of interest, and perspective-is an essential

Mesh:

Year:  2014        PMID: 24964694

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  8 in total

1.  Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand.

Authors:  Rungroj Krittayaphong; Unchalee Permsuwan
Journal:  Clin Drug Investig       Date:  2021-09-17       Impact factor: 3.580

2.  Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.

Authors:  Khachapon Nimdet; Surachat Ngorsuraches
Journal:  BMJ Open       Date:  2015-10-05       Impact factor: 2.692

3.  Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand.

Authors:  Unchalee Permsuwan; Piyameth Dilokthornsakul; Surasak Saokaew; Kednapa Thavorn; Nathorn Chaiyakunapruk
Journal:  Clinicoecon Outcomes Res       Date:  2016-09-21

4.  Cost-Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand.

Authors:  Kriengsak Vareesangthip; Chaicharn Deerochanawong; Dittaya Thongsuk; Nuch Pojchaijongdee; Unchalee Permsuwan
Journal:  Adv Ther       Date:  2022-01-17       Impact factor: 3.845

5.  The cost utility and budget impact of adjuvant racecadotril for acute diarrhea in children in Thailand.

Authors:  Tamlyn Anne Rautenberg; Ute Zerwes
Journal:  Clinicoecon Outcomes Res       Date:  2017-07-17

6.  Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health. Who decides? Who pays?

Authors:  Anthony Culyer; Kalipso Chalkidou; Yot Teerawattananon; Benjarin Santatiwongchai
Journal:  F1000Res       Date:  2018-01-17

Review 7.  A comparison of cost and cost-effectiveness analysis of two- implant-retained overdentures versus other removable prosthodontic treatment options for edentulous mandible: A systematic review.

Authors:  Shubhabrata Roy; Sourav Maji; Rahul Paul; Jayanta Bhattacharyya; Preeti Goel
Journal:  J Indian Prosthodont Soc       Date:  2020-04-07

8.  Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction.

Authors:  Rungroj Krittayaphong; Jirawit Yadee; Unchalee Permsuwan
Journal:  Clinicoecon Outcomes Res       Date:  2019-12-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.